Nitrated-fatty Acids Modulation of Type II Diabetes

University of Pittsburgh researchers have extracted a large quantity of total RNA from a robust laboratory strain of Hydractinia symbiolongicarpus, allowing for the development of powerful research tools. Hydractinia genomes contain many human disease genes not found in other species, and there is a growing need to better understand these genomes for research purposes. This isolation of total RNA could lead to the development of research tools to revolutionize the fields of stem cell biology and regenerative medicine research.

Nitro oleic acid reduces blood glucose levels in diabetic mice, demonstrating comparable or superior efficacy to rosiglitazone.

Description

Hydractinia is a small colonial invertebrate, traditionally found growing on snail shells inhabited by hermit crabs. It has an extraordinary ability to regenerate its entire body throughout its lifetime. As a result, it is emerging as a model system in biomedical research. The extraction of total RNA now provides an opportunity to build a yeast two-hybrid library to perform yeast two-hybrid screens and identify and study novel protein-protein interactions.

Applications

• Treatment of type 2 diabetes
• Management of insulin resistance
• Potential treatment for metabolic syndrome
• PPAR-γ modulation without traditional side effects
• Regulation of glucose metabolism

Advantages

• Reduces blood glucose without causing weight gain
• Superior insulin sensitization compared to existing treatments
• Avoids fluid retention side effects
• Different PPAR-γ binding mechanism than current drugs
• Extended activity through active metabolites

Invention Readiness

in vivo study has been completed using a murine model of diabetes (ob/ob -/- mice). The results showed that NO2-FA administration exerts anti-diabetic effects without the side effects commonly associated with thiazolidinediones (TZDs), such as peripheral edema, weight gain, and increased risk of cardiac failure.

IP Status

https://patents.google.com/patent/US10869850B2

Related Publication(s)

Li, Y., Zhang, J., Schopfer, F. J., Martynowski, D., Garcia-Barrio, M. T., Kovach, A., Suino-Powell, K., Baker, P. R. S., Freeman, B. A., Chen, Y. E., & Xu, H. E. (2008). Molecular recognition of nitrated fatty acids by PPARγ. Nature Structural & Molecular Biology, 15(8), 865–867. https://doi.org/10.1038/nsmb.1447

Quick Facts:
Reference Number
01545
Technology Type
Therapeutic Modality
Technology Subtype
Small Molecule
Therapeutic Areas
CardiovascularEndocrinology and Metabolic Diseases
Therapeutic Indications
Diabetes
Lead Inventor
Bruce Freeman
Department
Med-Pharmacology and Chemical Biology
All Tech Innovators
Bruce A. Freeman
Date Submitted
2007-08-01
Collections
Cardiometabolic